ReviewZeitschrift fur Gerontologie und Geriatrie2012
Osteoporosis and polypharmacy.
Review in Zeitschrift fur Gerontologie und Geriatrie, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of factors affecting medication adherence among patients with osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018Pooled it
- Effect of a one time guideline based educational video intervention on osteoporosis related knowledge.Archives of orthopaedic and trauma surgery · 2026Trial
- Midlife risk factors predict long-term hip fracture risk in women: a 35-yr follow-up.JBMR plus · 2026Article
- Association of Polypharmacy and Bone Mineral Density: A Cross-Sectional Analysis of Geriatric Inpatients in Germany.Journal of clinical medicine · 2026Article
- Age-adjusted Charlson comorbidity index is associated with the risk of osteoporosis in older fall-prone men: a retrospective cohort study.BMC geriatrics · 2024Article
- Pain score as a predictor of subsequent fragility fracture in postmenopausal patients with rheumatoid arthritis: A retrospective case-control study.Osteoporosis and sarcopenia · 2023Article
- National trends in osteoporosis medication use among Medicare beneficiaries with and without Alzheimer's disease/related dementias.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023Article
- Evaluation of the correlation between frailty and sleep quality among elderly patients with osteoporosis: a cross-sectional study.BMC geriatrics · 2022Article
- Usefulness of cortical thickness ratio of the third metacarpal bone for prediction of major osteoporotic fractures.Bone reports · 2022Article
- Rheumatoid arthritis in tight disease control is no longer risk of bone mineral density loss.Osteoporosis and sarcopenia · 2020Article
- [Osteoporosis and multimorbidity].Zeitschrift fur Gerontologie und Geriatrie · 2019Review
- The Association between Polypharmacy and Hip Fracture in Osteoporotic Women: A Nested Case-Control Study in South Korea.Clinical drug investigation · 2019Article
- Article
- Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment.Journal of geriatric oncology · 2014Article
- [Age and osteoporosis. Effects of aging on osteoporosis, the diagnostics and therapy].Der Internist · 2014Review
- Brains, bones, and aging: psychotropic medications and bone health among older adults.Current osteoporosis reports · 2012Review
- Bisphosphonates for Osteoporosis in Patients with Renal Insufficiency: Pharmacists' Practices and Beliefs.The Canadian journal of hospital pharmacyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is very common in elderly patients. Despite the severe health-related consequences for individual patients and the socioeconomic costs caused by osteoporotic fractures, treatment rates are still low. Due to drug interactions and patient compliance, polypharmacy is often mentioned as a reason for undertreatment. Several drugs have a direct or indirect effect on bone metabolism. The present paper discusses the risk of interactions of anti-osteoporotic drugs (oral and parenteral bisphosphonates, raloxifene, strontium ranelate, teriparatide, and denosumab) with other common medications in elderly patients and their impact on bone metabolism and fracture risk. In summary, the number and risk of drug interactions of all common anti-osteoporotic drugs are small and clinically rather irrelevant. However, patients with a polypharmacy are at a higher risk of fractures and should receive osteoporosis treatment, if indicated.
Indexed as
Identifiers
22806642What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.